Total Payments
$11,415
2024 Payments
$265.32
Companies
27
Transactions
107
Medicare Patients
17,051
Medicare Billing
$1.3M
Payment Breakdown by Category
Research$8,918 (78.1%)
Food & Beverage$2,498 (21.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,918 | 4 | 78.1% |
| Food and Beverage | $2,498 | 103 | 21.9% |
Payments by Type
Research
$8,918
4 transactions
General
$2,498
103 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $8,918 | 4 | $0 (2023) |
| ABBVIE INC. | $454.33 | 21 | $0 (2024) |
| GENZYME CORPORATION | $381.02 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $320.93 | 15 | $0 (2024) |
| Amgen Inc. | $274.46 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $220.35 | 8 | $0 (2023) |
| Incyte Corporation | $201.09 | 3 | $0 (2023) |
| STRATA Skin Sciences, Inc. | $72.13 | 1 | $0 (2022) |
| Galderma Laboratories, L.P. | $69.64 | 5 | $0 (2019) |
| Celgene Corporation | $58.02 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $265.32 | 8 | Amgen Inc. ($184.25) |
| 2023 | $9,270 | 11 | Novo Nordisk AS ($8,918) |
| 2022 | $300.50 | 13 | STRATA Skin Sciences, Inc. ($72.13) |
| 2021 | $15.37 | 1 | Janssen Biotech, Inc. ($15.37) |
| 2020 | $129.74 | 7 | AbbVie Inc. ($112.40) |
| 2019 | $534.71 | 18 | Novartis Pharmaceuticals Corporation ($187.40) |
| 2018 | $466.59 | 26 | Novartis Pharmaceuticals Corporation ($80.00) |
| 2017 | $433.40 | 23 | GENZYME CORPORATION ($117.97) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $6.16 | General |
| Category: Inflammation | ||||||
| 10/28/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: DERMATOLOGY | ||||||
| 09/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Inflammation | ||||||
| 05/15/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $32.11 | General |
| Category: Inflammation | ||||||
| 04/30/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Dermatology | ||||||
| 08/17/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $99.22 | General |
| Category: Immunology | ||||||
| 07/20/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $88.43 | General |
| Category: Dermatology | ||||||
| 05/18/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: IMMUNOLOGY | ||||||
| 04/26/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $94.03 | General |
| Category: Dermatology | ||||||
| 04/26/2023 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Dermatology | ||||||
| 03/31/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: IMMUNOLOGY | ||||||
| 03/16/2023 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Immunology | ||||||
| 01/09/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $8,371.38 | Research |
| Study: NN9924-4437 • Category: Diabetes | ||||||
| 01/09/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $313.18 | Research |
| Study: NN9924-4437 • Category: Diabetes | ||||||
| 01/09/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $175.66 | Research |
| Study: NN9924-4437 • Category: Diabetes | ||||||
| 01/09/2023 | Novo Nordisk AS | Rybelsus (Drug) | — | In-kind items and services | $57.54 | Research |
| Study: NN9924-4437 • Category: Diabetes | ||||||
| 12/28/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO, COMIRNATY | Food and Beverage | In-kind items and services | $14.46 | General |
| Category: DERMATOLOGY | ||||||
| 12/07/2022 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: DERMATOLOGY | ||||||
| 11/04/2022 | STRATA Skin Sciences, Inc. | XTRAC (Device) | Food and Beverage | In-kind items and services | $72.13 | General |
| Category: Dermatology | ||||||
| 08/19/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Immunology | ||||||
| 06/21/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: IMMUNOLOGY | ||||||
| 05/12/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.63 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9924-4437 | Novo Nordisk AS | $8,918 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,702 | 6,981 | $665,060 | $240,208 |
| 2022 | 20 | 4,146 | 9,460 | $874,897 | $303,343 |
| 2021 | 23 | 5,267 | 12,736 | $1.0M | $408,162 |
| 2020 | 23 | 4,936 | 11,761 | $899,864 | $373,367 |
Total Patients
17,051
Total Services
40,938
Medicare Billing
$1.3M
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 526 | 793 | $131,608 | $48,479 | 36.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 303 | 406 | $95,285 | $34,521 | 36.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 502 | 749 | $93,159 | $31,165 | 33.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 138 | 226 | $70,807 | $28,149 | 39.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 454 | 3,929 | $48,787 | $20,031 | 41.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 214 | 261 | $55,108 | $19,108 | 34.7% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 80 | 96 | $24,476 | $8,996 | 36.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $24,424 | $8,520 | 34.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 93 | 93 | $19,105 | $5,430 | 28.4% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 60 | 68 | $15,440 | $5,291 | 34.3% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 23 | 23 | $12,987 | $5,128 | 39.5% |
| 12034 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 7.6-12.5 cm | Office | 2023 | 13 | 16 | $9,914 | $3,925 | 39.6% |
| 11312 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 21 | 24 | $6,979 | $2,616 | 37.5% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 33 | 37 | $8,030 | $2,600 | 32.4% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 21 | 26 | $6,640 | $2,330 | 35.1% |
| 11307 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 19 | 24 | $6,230 | $2,196 | 35.2% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 16 | 18 | $5,746 | $2,146 | 37.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 17 | 18 | $9,280 | $2,021 | 21.8% |
| 11401 | Removal of noncancer skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 17 | 17 | $4,941 | $2,017 | 40.8% |
| 11306 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 17 | 21 | $4,814 | $1,740 | 36.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 25 | 25 | $4,725 | $1,516 | 32.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 15 | 16 | $3,746 | $1,383 | 36.9% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 15 | 15 | $2,830 | $901.47 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,034 | 1,335 | $225,935 | $74,862 | 33.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 815 | 1,061 | $134,238 | $43,511 | 32.4% |
About Jane Lynch
Jane Lynch is a Dermatopathology healthcare provider based in Staunton, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952370553.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jane Lynch has received a total of $11,415 in payments from pharmaceutical and medical device companies, with $265.32 received in 2024. These payments were reported across 107 transactions from 27 companies. The most common payment nature is "" ($8,918).
As a Medicare-enrolled provider, Lynch has provided services to 17,051 Medicare beneficiaries, totaling 40,938 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Location Staunton, VA
- Active Since 03/16/2006
- Last Updated 07/15/2016
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1952370553
Products in Payments
- Rybelsus (Drug) $8,918
- COSENTYX (Biological) $262.52
- Humira (Biological) $232.20
- DUPIXENT (Drug) $220.40
- Otezla (Drug) $205.95
- OPZELURA (Drug) $201.09
- SKYRIZI (Biological) $168.46
- TREMFYA (Drug) $139.78
- DUPIXENT (Biological) $91.17
- ATOPIC DERMATITIS - DISEASE (Drug) $86.97
- XTRAC (Device) $72.13
- Enbrel (Biological) $65.93
- ORACEA (Drug) $55.75
- TALTZ (Drug) $48.62
- RINVOQ (Biological) $41.64
- EUCRISA (Drug) $40.86
- XOLAIR (Biological) $38.75
- ENSTILAR (Drug) $38.64
- GUSELKUMAB (Biological) $36.21
- Tremfya (Drug) $33.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.